Literature DB >> 25232767

Markers of inflammation in recipients of continuous-flow left ventricular assist devices.

Liza Grosman-Rimon1, Michael A McDonald, Ira Jacobs, Laura C Tumiati, Stacey Pollock Bar-Ziv, Daniel J Shogilev, Amelia G Mociornita, Arash Ghashghai, Andrzej Chruscinski, David Z I Cherney, Vivek Rao.   

Abstract

Although the newer continuous-flow left ventricular assist devices (CF-LVADs) provide clinical advantages over the pulsatile pumps, the effects of low pulsatility on inflammation are incompletely understood. The objective of our study was to examine the levels of inflammatory mediators in CF-LVAD recipients compared with both healthy control subjects and heart failure patients who were candidates for CF-LVAD support. Plasma levels of chemokines, cytokines, and inflammatory markers were measured in 18 CF-LVAD recipients and compared with those of 14 healthy control subjects and 14 heart failure patients who were candidates for CF-LVADs. The levels of granulocyte macrophage-colony stimulating factor, macrophage inflammatory proteins-1β, and macrophage-derived chemokine were significantly higher in the CF-LVAD group compared with both the heart failure and the healthy control groups, whereas no significant differences were observed between the healthy control subjects and the heart failure groups. Compared with the healthy controls, C-reactive protein, interferon gamma-induced protein-10, monocyte chemotactic protein-1, and interleukin-8 levels were significantly higher in both the CF-LVAD and heart failure groups, but no significant differences were observed between the CF-LVAD recipients and the heart failure patients. Inflammatory markers were elevated in CF-LVAD recipients compared with healthy control subjects and the heart failure patients. Further studies should investigate the clinical implications of elevated levels of inflammation in CF-LVAD recipients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25232767     DOI: 10.1097/MAT.0000000000000129

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  11 in total

1.  Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant.

Authors:  Melana Yuzefpolskaya; Bruno Bohn; Mojdeh Nasiri; Amelia M Zuver; Drew D Onat; Eugene A Royzman; Joseph Nwokocha; Melissa Mabasa; Alberto Pinsino; Danielle Brunjes; Antonia Gaudig; Autumn Clemons; Pauline Trinh; Stephania Stump; Marla J Giddins; Veli K Topkara; A Reshad Garan; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Maryjane A Farr; Renu Nandakumar; Anne-Catrin Uhlemann; Paolo C Colombo; Ryan T Demmer
Journal:  J Heart Lung Transplant       Date:  2020-02-13       Impact factor: 10.247

Review 2.  Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery.

Authors:  Karolina K Marinescu; Nir Uriel; Douglas L Mann; Daniel Burkhoff
Journal:  Expert Rev Med Devices       Date:  2016-12-22       Impact factor: 3.166

3.  Delayed febrile response with bloodstream infections in patients with continuous-flow left ventricular assist devices.

Authors:  Christopher A Wrobel; Mark H Drazner; Colby R Ayers; David D Pham; Ricardo M La Hoz; Justin L Grodin; Sonia Garg; Pradeep P A Mammen; Robert M Morlend; Faris Araj; Alpesh A Amin; William K Cornwell; Jennifer T Thibodeau
Journal:  J Investig Med       Date:  2019-01-29       Impact factor: 2.895

4.  Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices.

Authors:  Corey E Tabit; Mitchell J Coplan; Phetcharat Chen; Valluvan Jeevanandam; Nir Uriel; James K Liao
Journal:  J Heart Lung Transplant       Date:  2017-06-08       Impact factor: 10.247

Review 5.  The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery.

Authors:  Luise Holzhauser; Gene Kim; Gabriel Sayer; Nir Uriel
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 6.  Reverse Remodeling With Left Ventricular Assist Devices.

Authors:  Daniel Burkhoff; Veli K Topkara; Gabriel Sayer; Nir Uriel
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 23.213

Review 7.  Pathophysiology of heart failure and frailty: a common inflammatory origin?

Authors:  Lavanya Bellumkonda; Daniel Tyrrell; Scott L Hummel; Daniel R Goldstein
Journal:  Aging Cell       Date:  2017-03-07       Impact factor: 9.304

8.  Circulating biomarkers in acute myofascial pain: A case-control study.

Authors:  Liza Grosman-Rimon; William Parkinson; Suneel Upadhye; Hance Clarke; Joel Katz; John Flannery; Philip Peng; Dinesh Kumbhare
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 9.  Considerations for Heart Failure Care During the COVID-19 Pandemic.

Authors:  Ersilia M DeFilippis; Nosheen Reza; Elena Donald; Michael M Givertz; JoAnn Lindenfeld; Mariell Jessup
Journal:  JACC Heart Fail       Date:  2020-06-03       Impact factor: 12.035

10.  Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices.

Authors:  Jeanine M Walenga; Tania A Torres; Walter P Jeske; Jeffrey Schwartz; Vicki Escalante; Joshua D Newman; Mamdouh Bakhos
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.